Mesoblast Prepares for Resubmission of Biologics License Application
NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational and financial activity report for the second quarter ended December 31, 2021.
Key operational highlights for the quarter
Activities supporting potential resubmission of the Biologics License Application (BLA) for remestemcel-L in the trea...
>>> Read more: Appendix 4C Quarterly Activity Report
NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational and financial activity report for the second quarter ended December 31, 2021.
Key operational highlights for the quarter
Activities supporting potential resubmission of the Biologics License Application (BLA) for remestemcel-L in the trea...
>>> Read more: Appendix 4C Quarterly Activity Report
